These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26276965)

  • 1. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.
    van Vollenhoven RF; Fleischmann RM; Furst DE; Lacey S; Lehane PB
    J Rheumatol; 2015 Oct; 42(10):1761-6. PubMed ID: 26276965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.
    van Vollenhoven RF; Emery P; Bingham CO; Keystone EC; Fleischmann RM; Furst DE; Tyson N; Collinson N; Lehane PB
    Ann Rheum Dis; 2013 Sep; 72(9):1496-502. PubMed ID: 23136242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.
    van Vollenhoven RF; Emery P; Bingham CO; Keystone EC; Fleischmann R; Furst DE; Macey K; Sweetser M; Kelman A; Rao R
    J Rheumatol; 2010 Mar; 37(3):558-67. PubMed ID: 20110520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
    Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R
    J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.
    De Keyser F; Hoffman I; Durez P; Kaiser MJ; Westhovens R;
    J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study.
    Vassilopoulos D; Delicha EM; Settas L; Andrianakos A; Aslanidis S; Boura P; Katsounaros M; Athanassiou P; Tempos K; Skarantavos G; Antoniadis C; Papazoglou S; Sakkas L; Galanopoulou V; Skopouli F; Boki K; Daoussis D; Vritzali E; Sfikakis PP
    Clin Exp Rheumatol; 2016; 34(5):893-900. PubMed ID: 27383049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
    Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
    J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
    Rigby WF; Mease PJ; Olech E; Ashby M; Tole S
    J Rheumatol; 2013 May; 40(5):599-604. PubMed ID: 23547218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
    Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
    Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
    Lebwohl M; Leonardi C; Griffiths CE; Prinz JC; Szapary PO; Yeilding N; Guzzo C; Li S; Hsu MC; Strober B
    J Am Acad Dermatol; 2012 May; 66(5):731-41. PubMed ID: 21930328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs.
    Valleala H; Korpela M; Hienonen-Kempas T; Immonen K; Lähteenmäki J; Uusitalo T; Komulainen R; Möttönen T; Hannonen P
    J Clin Rheumatol; 2015 Jan; 21(1):24-30. PubMed ID: 25539430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
    Popa C; Leandro MJ; Cambridge G; Edwards JC
    Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.
    Weinblatt ME; Moreland LW; Westhovens R; Cohen RB; Kelly SM; Khan N; Pappu R; Delaet I; Luo A; Gujrathi S; Hochberg MC
    J Rheumatol; 2013 Jun; 40(6):787-97. PubMed ID: 23588946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
    Gottenberg JE; Ravaud P; Bardin T; Cacoub P; Cantagrel A; Combe B; Dougados M; Flipo RM; Godeau B; Guillevin L; Le Loët X; Hachulla E; Schaeverbeke T; Sibilia J; Baron G; Mariette X;
    Arthritis Rheum; 2010 Sep; 62(9):2625-32. PubMed ID: 20506353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.
    den Broeder AA; Verhoef LM; Fransen J; Thurlings R; van den Bemt BJF; Teerenstra S; Boers N; den Broeder N; van den Hoogen FHJ
    Trials; 2017 Aug; 18(1):403. PubMed ID: 28854956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
    Yoo DH; Suh CH; Shim SC; Jeka S; Cons-Molina FF; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kwon TS; Park W
    Ann Rheum Dis; 2017 Mar; 76(3):566-570. PubMed ID: 27624791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
    Mease PJ; Cohen S; Gaylis NB; Chubick A; Kaell AT; Greenwald M; Agarwal S; Yin M; Kelman A
    J Rheumatol; 2010 May; 37(5):917-27. PubMed ID: 20194448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.